Home   >  
Protease/Metabolic Enzyme
  >  
HIV Protease
  >   Deuterated Atazanivir-D3-1
Deuterated Atazanivir-D3-1 Chemical Structure

Deuterated Atazanivir-D3-1

Data Sheet For research use only. Not for human use.
Cat. No. :BCP03513CAS No. :1092540-56-1Purity:98%
 Tel: 0086-17754423994   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 1092540-56-1 Cat. No. BCP03513
Name Deuterated Atazanivir-D3-1
Synonyms CTP-518;CTP518;CTP 518;
SMILES
Chemical Name
Formula C38H37D15N6O7 M. Wt 719.96
Purity 98% Storage Store at 4-8°C
Description Atazanivir-D3-2 is an azapeptide derivative and a HIV protease inhibitor. Atazanivir-D3-2 is a deuterium-containing agent. Atazanivir-D3-2 displays a shorter half life than atazanavir, as well as Atazanivir-D3-1 and Atazanivir-D3-3. Atazanavir sulfate prevents the formation of mature HIV virions in HIV-1 infected cells by selectively inhibiting the virus-specific processing of certain polyproteins (viral Gag and Gag-Pol). Atazanavir sulfate is currently approved for the treatment of HIV infection. Atazanavir is contraindicated for co-administration with medicines that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Due to inhibitory effects of atazanavir on CYP3A, CYP2C8, and UGTIAl, caution is advised when prescribing. Common adverse events associated with atazanavir include hyperbilirubinemia, rash, nausea, headache, mid jaundice/sclcral icterus.
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Deuterated Atazanivir-D3-1 supplier,Deuterated Atazanivir-D3-1 purchase,Deuterated Atazanivir-D3-1 manufacturer,Deuterated Atazanivir-D3-1 distributor,Deuterated Atazanivir-D3-1 cost,Deuterated Atazanivir-D3-1 buy,Deuterated Atazanivir-D3-1 for sale

0086-13720134139